Earnings summaries and quarterly performance for HERBALIFE.
Executive leadership at HERBALIFE.
Stephan Gratziani
Detailed
Chief Executive Officer
CEO
FL
Frank Lamberti
Detailed
Chief Commercial Officer
HW
Henry Wang
Detailed
Chief Legal Officer and Corporate Secretary
JD
John DeSimone
Detailed
Chief Financial Officer
MO
Michael O. Johnson
Detailed
Executive Chairman
RL
Rob Levy
Detailed
President, Worldwide Markets
Board of directors at HERBALIFE.
CD
Celine Del Genes
Detailed
Director
DM
Don Mulligan
Detailed
Director
JM
Juan Miguel Mendoza
Detailed
Director
LC
Lynda Cloud
Detailed
Director
MO
Maria Otero
Detailed
Director
MJ
Michael J. Levitt
Detailed
Director
PM
Perkins Miller
Detailed
Director
RH
Richard H. Carmona
Detailed
Director
RM
Rodica Macadrai
Detailed
Director
SL
Sophie L’Hélias
Detailed
Director
Research analysts who have asked questions during HERBALIFE earnings calls.
Chasen Bender
Citigroup
7 questions for HLF
Also covers: NUS
Douglas Lane
Water Tower Research
7 questions for HLF
Also covers: AOUT, BBW, BSET +8 more
Christina Tan
Mizuho
5 questions for HLF
HH
Hale Holden
Barclays
3 questions for HLF
Also covers: ACCO, ARKO, BGS +2 more
John Baumgartner
Mizuho Securities
3 questions for HLF
Also covers: BRBR, BYND, GIS +15 more
RR
Robert Rigby
Bank of America
3 questions for HLF
Also covers: BGS
Karru Martinson
Jefferies
2 questions for HLF
Also covers: ARKO, BGS, RAC +1 more
LB
Linda Bolton-Weiser
D.A. Davidson & Co.
2 questions for HLF
Also covers: CLX, ELF, FLWS +14 more
JV
Jeff Van Sinderen
B. Riley Securities
1 question for HLF
Also covers: BTMD, BYRN, CDRE +11 more
Recent press releases and 8-K filings for HLF.
Herbalife discusses strategic evolution, new initiatives, and debt reduction goals at BofA Securities conference
HLF
New Projects/Investments
Debt Issuance
Revenue Acceleration/Inflection
- Herbalife's CEO, Stephan Gratziani, who has been in the role for seven months and was a distributor for over 30 years, is driving the company's strategy to become the "Netflix of health and wellness".
- The company is advancing digital and product personalization with the "Protocol" app (a personal health operating system in beta) and a 51% controlling interest acquisition of Link BioSciences for personalized product formulation, both targeting commercial availability in North America by summer 2026.
- Herbalife has reduced its leverage ratio to 2.8 times (from 3.9 times in March 2024) and prioritizes further debt reduction, aiming for $1.4 billion gross debt by 2028 (a $1 billion reduction from Q2 2024 levels). Share repurchases are not a priority.
- The company expects net sales growth in Q4 2025 and for next year (2026), globally and in the US, building on Q3 2025 growth. Adjusted EBITDA margins have improved from 11.3% in 2023 to north of 13% this year (2025).
Dec 2, 2025, 1:10 PM
Herbalife Outlines Strategic Evolution, Growth Outlook, and Debt Reduction Priorities
HLF
New Projects/Investments
Revenue Acceleration/Inflection
M&A
- Herbalife is strategically evolving to become the "Netflix of health and wellness" and the world's largest health and wellness platform, moving beyond nutritional supplements to encompass a holistic health picture through data. This includes the Protocol app, a personal health operating system in beta, with full North American commercial availability planned for July next year , and the 51% acquisition of Link BioSciences for personalized product formulation, expected in beta by summer next year.
- The company reported strong Q3 growth globally and in the US, and anticipates global growth in Q4 and next year. Adjusted EBITDA margins are improving, with 11.3% in 2023, 12.7% in 2024, and projected to be north of 13% in 2025.
- Herbalife's primary financial priority is to reduce gross debt by $1 billion to $1.4 billion by 2028, aiming for a leverage ratio below two times by then. The company is a capital-light cash generator, and share repurchases are not a priority.
Dec 2, 2025, 1:10 PM
Herbalife Reports Q3 2025 Results with Net Sales Growth and Reduced Leverage
HLF
Earnings
Guidance Update
Product Launch
- Herbalife reported net sales of $1.3 billion, up 2.7% year-over-year, and adjusted EBITDA of $163 million for Q3 2025, exceeding the high end of its guidance range.
- The company achieved worldwide net sales growth of 3.2% on a constant currency basis and North America returned to net sales growth for the first time since Q2 2021.
- Operating cash flows were $139 million, a 40% increase from Q3 2024, and the total leverage ratio was reduced to 2.8 times.
- Herbalife introduced new products and initiatives, including the launch of HL Skin in EMEA, the upcoming commercial launch of Baseline in the US and Puerto Rico, and the acquisition of Linked Bioscience for personalized supplements.
- For the full year 2025, the company updated its guidance, expecting net sales to range from a slight decline of 0.3% to growth of 0.7% (reported) and adjusted EBITDA between $645 million and $655 million (reported).
Nov 5, 2025, 10:30 PM
Herbalife Reports Q3 2025 Results, Exceeds Guidance, and Updates FY 2025 Outlook
HLF
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Herbalife reported Q3 2025 net sales of $1.3 billion, a 2.7% increase year-over-year (+3.2% at constant currency), and Adjusted EBITDA of $163 million, exceeding guidance.
- The company achieved an Adjusted diluted EPS of $0.50 for Q3 2025 and generated $139 million in net cash from operating activities.
- Herbalife fully repaid $147 million of the remaining principal on its 2025 Notes at maturity and reduced its total leverage ratio to 2.8x as of September 30, 2025, exceeding its 3.0x commitment.
- For fiscal year 2025, the company updated its guidance, projecting reported net sales to be (0.3)% to +0.7% year-over-year and Adjusted EBITDA to be between $645 million and $655 million.
- North America returned to net sales growth, marking its first year-over-year quarterly increase since Q2 2021, and new distributor growth was seen in three out of five regions, led by North America with a 17% year-over-year increase.
Nov 5, 2025, 10:30 PM
Herbalife Reports Q3 2025 Financial Results with Net Sales Above Guidance
HLF
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Herbalife reported net sales of $1.3 billion for the third quarter ended September 30, 2025, an increase of 2.7% year-over-year, which was above the midpoint of its guidance range.
- Adjusted EBITDA for Q3 2025 was $163.0 million, exceeding guidance, and adjusted diluted EPS was $0.50.
- North America net sales increased by 1.0% year-over-year, marking the region's first quarterly gain since Q2 2021.
- The company repaid $147.3 million of remaining principal on its 2025 Notes, reducing the total leverage ratio to 2.8x at September 30, 2025.
- Herbalife tightened its full-year 2025 guidance ranges for net sales, adjusted EBITDA, and capital expenditures.
Nov 5, 2025, 9:27 PM
Herbalife Reports Q3 2025 Financial Results
HLF
Earnings
Guidance Update
Revenue Acceleration/Inflection
- Herbalife reported Q3 2025 net sales of $1.3 billion, an increase of 2.7% year-over-year, and adjusted EBITDA of $163.0 million, which exceeded guidance.
- North America net sales increased by 1.0% year-over-year, marking the region's first quarterly gain since Q2 2021.
- Diluted EPS was $0.42, with adjusted diluted EPS of $0.50 for Q3 2025.
- The company tightened its full-year 2025 guidance ranges for net sales, adjusted EBITDA, and capital expenditures.
- Herbalife repaid $147.3 million of remaining principal on its 2025 Notes, reducing the total leverage ratio to 2.8x at September 30, 2025.
Nov 5, 2025, 9:10 PM
Herbalife Discusses Strategic Transformation and Improved North America Sales
HLF
M&A
New Projects/Investments
Revenue Acceleration/Inflection
- Herbalife is undergoing a strategic transformation to become a digital-first health and wellness company, community, and platform, leveraging its network of over 2 million distributors and 60,000 brick-and-mortar locations.
- This transformation includes the acquisition of ProveIt, Pro2col app, and Link BioSciences in a single transaction, with Link BioSciences providing a controlling interest in personalized nutrition technology and the Pro2col app expected to drive incremental sales and subscription revenue.
- North America net sales trends have improved, with July 2025 marking the first year-over-year volume growth in the region since April 2021, following previous declines of 8% in Q1 and 6% in Q2.
- The company has exceeded its EBITDA guidance for six or seven straight quarters and improved adjusted EBITDA margins from 11.3% in 2023 to 12.7% last year, with further improvement expected.
Sep 2, 2025, 9:52 PM
Quarterly earnings call transcripts for HERBALIFE.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more